Document Detail


Rituximab as a single agent in the management of adult patients with haemophilia A and inhibitors: marked reduction in inhibitor level and clinical improvement in bleeding but failure to eradicate the inhibitor.
MedLine Citation:
PMID:  19149851     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Management of patients with severe haemophilia A who develop inhibitors is difficult and expensive. Standard treatment of this complication is immune tolerance induction (ITI) therapy, but is successful in only 60-80% of the patients. Failure of ITI results in a higher risk of morbidity and mortality. We used rituximab, an anti-CD20 antibody, in three patients with severe haemophilia A and inhibitors. Two patients with high-titre inhibitors had marked reduction in the inhibitor level; the third patient with low-titre inhibitor had a disappearance of the inhibitor. All patients improved clinically, with fewer bleeding episodes and a better quality of life. Inhibitor level increased with time in these patients, but the clinical benefit continued in two patients with high-titre inhibitors initially, after a follow-up of 48 and 22 months. One of the patients with concomitant human immunodeficiency virus (HIV) infection and a very low CD4 lymphocyte count developed severe truncal herpes zoster after the third weekly dose of rituximab. Caution is required in such patients, and we recommend avoiding rituximab use in HIV-infected patients with very low CD4 lymphocyte count. In conclusion, rituximab is useful in reducing the inhibitor level with clinical benefit in patients with severe haemophilia A and inhibitors, but it cannot eradicate the inhibitors for long periods with the currently used protocol of up to five doses.
Authors:
A Aleem; A Saidu; H Abdulkarim; A R Al-Diab; A Al-Sagheer; A Qayum; A K Al-Momen
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  15     ISSN:  1365-2516     ISO Abbreviation:  Haemophilia     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-19     Completed Date:  2009-08-04     Revised Date:  2009-10-21    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  England    
Other Details:
Languages:  eng     Pagination:  210-6     Citation Subset:  IM    
Affiliation:
Department of Medicine, Division of Haematology/Oncology, College of Medicine, King Khalid University Hospital, Riyadh, Saudi Arabia. aameraleem@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Monoclonal / therapeutic use*
Factor VIII / immunology*
Hemophilia A / complications,  drug therapy*,  immunology
Hemorrhage / prevention & control
Humans
Immune Tolerance / drug effects
Immunologic Factors / therapeutic use*
Isoantibodies / blood*
Male
Young Adult
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunologic Factors; 0/Isoantibodies; 0/rituximab; 9001-27-8/Factor VIII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for differe...
Next Document:  Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density.